Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study

RecruitingOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions

COPD

Interventions

DRUG

Beclometasone/Formoterol/Glycopyrronium 88 µg/5 µg/9 µg DPI (Trimbow® 88 µg/5 µg/9 µg in NEXThaler device)

observational, prospective, multicentric, international, cohort study

Trial Locations (1)

RECRUITING

Pitié-Salpêtrière Hospital, Paris